Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, thes...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/full |
id |
doaj-04253511564444b3b968b905ca10bb30 |
---|---|
record_format |
Article |
spelling |
doaj-04253511564444b3b968b905ca10bb302021-01-15T15:23:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-12-011110.3389/fphar.2020.586892586892Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic TargetsCarlamaria Zoja0Christodoulos Xinaris1Christodoulos Xinaris2Daniela Macconi3Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyUniversity of Nicosia Medical School, Nicosia, CyprusIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, ItalyDiabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, these therapeutic approaches can provide only partial renoprotection if started late in the course of the disease. One major limitation in developing efficient therapies for DN is the complex pathobiology of the diabetic kidney, which undergoes a set of profound structural, metabolic and functional changes. Despite these difficulties, experimental models of diabetes have revealed promising therapeutic targets by identifying pathways that modulate key functions of podocytes and glomerular endothelial cells. In this review we will describe recent advances in the field, analyze key molecular pathways that contribute to the pathogenesis of the disease, and discuss how they could be modulated to prevent or reverse DN.https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/fulldiabetic nephropathyrenin-angiotensin systemangiotensin 1–7sirtuinsnotch signalingthyroid hormone signaling |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carlamaria Zoja Christodoulos Xinaris Christodoulos Xinaris Daniela Macconi |
spellingShingle |
Carlamaria Zoja Christodoulos Xinaris Christodoulos Xinaris Daniela Macconi Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets Frontiers in Pharmacology diabetic nephropathy renin-angiotensin system angiotensin 1–7 sirtuins notch signaling thyroid hormone signaling |
author_facet |
Carlamaria Zoja Christodoulos Xinaris Christodoulos Xinaris Daniela Macconi |
author_sort |
Carlamaria Zoja |
title |
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets |
title_short |
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets |
title_full |
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets |
title_fullStr |
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets |
title_full_unstemmed |
Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets |
title_sort |
diabetic nephropathy: novel molecular mechanisms and therapeutic targets |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2020-12-01 |
description |
Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes mellitus and the leading cause of end-stage kidney disease. The standard treatments for diabetic patients are glucose and blood pressure control, lipid lowering, and renin-angiotensin system blockade; however, these therapeutic approaches can provide only partial renoprotection if started late in the course of the disease. One major limitation in developing efficient therapies for DN is the complex pathobiology of the diabetic kidney, which undergoes a set of profound structural, metabolic and functional changes. Despite these difficulties, experimental models of diabetes have revealed promising therapeutic targets by identifying pathways that modulate key functions of podocytes and glomerular endothelial cells. In this review we will describe recent advances in the field, analyze key molecular pathways that contribute to the pathogenesis of the disease, and discuss how they could be modulated to prevent or reverse DN. |
topic |
diabetic nephropathy renin-angiotensin system angiotensin 1–7 sirtuins notch signaling thyroid hormone signaling |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2020.586892/full |
work_keys_str_mv |
AT carlamariazoja diabeticnephropathynovelmolecularmechanismsandtherapeutictargets AT christodoulosxinaris diabeticnephropathynovelmolecularmechanismsandtherapeutictargets AT christodoulosxinaris diabeticnephropathynovelmolecularmechanismsandtherapeutictargets AT danielamacconi diabeticnephropathynovelmolecularmechanismsandtherapeutictargets |
_version_ |
1724336671251496960 |